Noramco, Inc., a global producer of controlled substances for the pharmaceutical industry, and AMPAC Fine Chemicals (AFC), a manufacturer of Active Pharmaceutical Ingredients (APIs) with cGMP facilities in the U.S., have entered strategic partnership to produce certain US DEA controlled substances for use in the treatment of addiction, abuse prevention, cannabinoids for clinical indications, and for the treatment of attention deficit hyperactivity disorder (ADHD). AFC will serve as a contract ma...